President Donald Trump signed an executive order on April 18, 2026, directing the Food and Drug Administration to expedite review of psychedelic drugs previously designated as breakthrough therapies, with a specific focus on ibogaine for treating veterans suffering from trauma-related conditions.
The order aims to dismantle bureaucratic delays in approving psychedelic-based treatments, improve data sharing between federal health agencies and the Department of Veterans Affairs, and create a pathway for faster rescheduling of substances that gain FDA approval. Trump framed the move as a historic reform to accelerate access to treatments showing promise in clinical trials for severe depression, anxiety, and post-traumatic stress.
He cited a 2024 Stanford University study in which 30 special operations veterans with traumatic brain injuries received ibogaine treatment and experienced an 80 to 90 percent reduction in depression and anxiety symptoms within one month. The president also announced a $50 million federal investment in ibogaine research, matching a prior commitment by Texas Republican leaders, and said the order would enable use of the drug under right-to-try laws for critically ill patients.
Despite its potential, ibogaine remains classified as a Schedule I substance under federal law due to known risks, including cardiovascular toxicity that can trigger fatal heart arrhythmias. The National Institutes of Health halted research on the compound in the 1990s over these safety concerns, and experts like Frederick Barrett of Johns Hopkins warn that studying ibogaine in the U.S. Has been extremely demanding because of its toxicity profile.
The announcement brought together an unusual coalition in the Oval Office, including Health and Human Services Secretary Robert F. Kennedy Jr., podcast host Joe Rogan, and former Navy SEAL Marcus Luttrell, who credited ibogaine with transforming his own mental health after combat service. Rogan said he had shared research with Trump, who responded by pushing for immediate FDA action.
FDA Commissioner Marty Makary said the agency would issue national priority vouchers the following week for three psychedelics, allowing accelerated approval if they align with federal health priorities — the first time such a mechanism has been applied to psychedelic substances. The FDA is also preparing to authorize the first-ever human trials of ibogaine in the United States.
While veterans’ advocacy groups and some conservative lawmakers have long supported psychedelic research for trauma and addiction, the move has surprised long-standing researchers who caution that safety risks remain inadequately addressed. The policy shift reflects growing bipartisan interest in psychedelic medicine, though it places the administration at odds with decades of federal drug classification and safety protocol.
What specific actions does the executive order require of the FDA?
The order directs the FDA to expedite review of psychedelics with breakthrough therapy designation, improve data sharing with the Department of Veterans Affairs, and facilitate faster rescheduling of approved psychedelic substances.
Why has ibogaine been difficult to study in the United States despite reported benefits?
Ibogaine’s known cardiovascular toxicity, including risk of fatal heart arrhythmias, has made clinical research challenging and led to the discontinuation of NIH-funded studies in the 1990s over safety concerns.
